Ipsen appoints Catherine Bradley director

Ipsen, a global biopharmaceutical company, announced the co-optation of Catherine Ashmore Bradley as an independent Director to its Board of Directors, effective July 29, 2026. Bradley succeeds Ms. Witts, who stepped down after the Annual General Meeting on May 13, 2026. Bradley brings over 30 years of experience in investment banking and financial markets, having held senior positions at Bank of America — Merrill (company), UBS Group — Credit Suisse, and BNP Paribas. She also has extensive audit committee experience, having chaired audit committees at the United Kingdom — Financial Conduct Authority, Aberdeen plc, Stellantis — PSA Group, and Worldpay. Currently, she serves as Chair of Interactive Investor and as a non-executive director at Johnson Electric Holdings and easyJet. The Board also appointed Bradley as Chair of the Audit Committee and a member of the Compensation Committee. Her appointment will be ratified at the next Annual Shareholders' Meeting and, if approved, will continue until the 2029 meeting. Following this appointment, Ipsen's Board comprises 14 directors with equal gender representation.